NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Shanghai Vitalgen BioPharma Co., Ltd.

Shanghai Vitalgen BioPharma Co., Ltd.

Private
ShanghaiHealthcare & Life Scienceshttp://www.vitalgen.com/

Last Round

Series C

May 12, 2022

Total Funding Raised

$136.35M

Company Overview

Shanghai Vitalgen BioPharma Co., Ltd. is a biotechnology company that develops transformative gene and cell therapies for hereditary, neurodegenerative, and metabolic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

gene therapyCDMObiotech CDMOcontract development and manufacturing organizationviral vector manufacturinggenetic medicineAAV capsidsviral vector platformlipid nanoparticlesCRISPR toolsbiotech manufacturingdrug discoverygene therapy pipelinerare disease therapeuticsbiopharma services

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Shanghai Vitalgen BioPharma Co., Ltd. Comparables

Compare Shanghai Vitalgen BioPharma Co., Ltd. with similar companies based on industry and business-model similarity.

Shanghai Vitalgen BioPharma Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
PackGene Biotech
83%
Zhejiang Innoforce Pharmaceuticals
82%
uBriGene Biosciences
79%

Shanghai Vitalgen BioPharma Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CMay 12, 2022
Series BMay 17, 2021
Series ADec 2, 2019
AngelNov 1, 2018

Shanghai Vitalgen BioPharma Co., Ltd. Investors

Notable investors and investment history

Shanghai Vitalgen BioPharma Co., Ltd. investors
InvestorRounds
CDG CapitalSeries C
Sherpa Healthcare PartnersSeries C
Kunlun CapitalSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 12, 2022

    $55.2M round with CDG Capital, Kunlun Capital, and Sherpa Healthcare Partners.

  • May 17, 2021

    $63M round completed.

Shanghai Vitalgen BioPharma Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Shanghai Vitalgen BioPharma Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Shanghai Vitalgen BioPharma Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Employee Range12
Year Founded2020
Last FundingMay 12, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.